just a reminder for holders or those looking at investing in PRR ...
from the PRR website ...
" Prima BioMed’s leading drug, CVac™ targets cancer cells expressing mucin-1 which are prolific on the surface of many cancers.
Mucin-1 protein is not only common in ovarian cancer; it is also expressed in prostate, kidney, pancreatic, breast, colon, and lung cancer cells.
This significantly opens the market for CVac™ to be applied to a variety of cancer types which is unique compared to other drug discovery and development companies. "
the link http://www.primabiomed.com.au/trial/faq.php
... what this means is that if indeed Cvac is ' commercialised ' as such .... the target / forward revenue estimates are for tackling only 10 % of the Ovarian Cancer market .... and if the door is then openeed to indeed become a therapy to tackle other mucin - 1 expressing cancers ... the revenues will be far in excess of those stated ...
PRR Price at posting:
14.8¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)